2012
DOI: 10.1016/j.mito.2011.11.001
|View full text |Cite
|
Sign up to set email alerts
|

Functionalized nanosystems for targeted mitochondrial delivery

Abstract: Mitochondrial dysfunction including oxidative stress and DNA mutations underlies the pathology of various diseases including Alzheimer’s disease and diabetes, necessitating the development of mitochondria targeted therapeutic agents. Nanotechnology offers unique tools and materials to target therapeutic agents to mitochondria. As discussed in this paper, a variety of functionalized nanosystems including polymeric and metallic nanoparticles as well as liposomes are more effective than plain drug and non-functio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
40
0

Year Published

2012
2012
2021
2021

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 67 publications
(41 citation statements)
references
References 82 publications
1
40
0
Order By: Relevance
“…Based on the mitochondrial membrane features, physicochemical properties of NPs have been well characterized. 63 Outer mitochondrial membrane can permeate NPs up to 3 nm in size and molecules with a molecular weight less than 5000 daltons through voltage-dependent anion channels. If the therapeutic target is within the mitochondrial matrix, the drug will also have to cross the inner membrane, which has a strong negative potential, thus drug lipophilicity, charge, and polar surface area positively influence the delivery that may be achieved also by integrating mitochondrial translocation ligands and/ or positively charged ligands into the NP design.…”
Section: Specific Intracellular Nanoparticle Targetingmentioning
confidence: 99%
“…Based on the mitochondrial membrane features, physicochemical properties of NPs have been well characterized. 63 Outer mitochondrial membrane can permeate NPs up to 3 nm in size and molecules with a molecular weight less than 5000 daltons through voltage-dependent anion channels. If the therapeutic target is within the mitochondrial matrix, the drug will also have to cross the inner membrane, which has a strong negative potential, thus drug lipophilicity, charge, and polar surface area positively influence the delivery that may be achieved also by integrating mitochondrial translocation ligands and/ or positively charged ligands into the NP design.…”
Section: Specific Intracellular Nanoparticle Targetingmentioning
confidence: 99%
“…1,5 As a consequence, mitochondrial dysfunction has been linked to a range of diseases in these tissues (and others) including neurodegenerative and neuromuscular disorders, cancer, ischemiareperfusion injury, metabolic diseases such as diabetes and obesity, chronic autoimmune inflammatory diseases, kidney and liver diseases, and aging. 1,3,[6][7][8][9][10] In spite of the clinical relevance of these mitochondrial-related diseases many still lack effective therapeutic options. 1,11 The ability to design mitochondrial-targeting systems may therefore provide valuable alternative strategies to enhance therapeutic outcomes of mitochondrial-related diseases while at the same time minimizing side effects associated with the therapeutic molecules.…”
Section: Introductionmentioning
confidence: 99%
“…154 Thus far, most studies have primarily developed metal oxide or liposomal NPs for delivery to the mitochondria. Delivery to the mitochondria has also been based on electrostatic interactions between the NP and the organelle.…”
Section: Nanoparticle Applications In Biologymentioning
confidence: 99%